Related Experiment Videos
Lung transplantation in interstitial lung disease
R Sulica1, A Teirstein, M L Padilla
1Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA.
Current Opinion in Pulmonary Medicine
|October 5, 2001
Summary
Lung transplantation offers significant survival benefits for patients with interstitial lung disease, including idiopathic pulmonary fibrosis. This therapy is effective and comparable to other transplant indications, managing respiratory failure.
Area of Science:
- Pulmonology
- Transplant Surgery
- Critical Care Medicine
Background:
- Interstitial lung disease (ILD) encompasses various conditions, some leading to fibrosing stages and respiratory failure.
- Lung transplantation is a definitive treatment for select ILD patients.
- Idiopathic pulmonary fibrosis (IPF) presents high pre-transplant mortality but shows survival benefit post-transplant.
Purpose of the Study:
- To review lung transplantation for interstitial lung diseases.
- To analyze indications, procedures, and outcomes.
- To discuss challenges like morbidity, mortality, and disease recurrence.
Main Methods:
- Literature review of lung transplantation outcomes in ILD.
- Analysis of data on specific ILDs and overall ILD transplant cohorts.
- Examination of factors influencing post-transplant survival and recurrence.
Main Results:
- Lung transplantation provides significant survival benefit for IPF patients.
- Disease recurrence is observed in several ILDs post-transplantation.
- Overall survival for ILD lung transplant recipients is comparable to other indications.
Conclusions:
- Lung transplantation is a well-tolerated and effective treatment for end-stage respiratory failure due to ILD.
- Careful patient selection and management are crucial.
- Further research into recurrence and long-term outcomes is warranted.